Skip to content

[Webinar] Why modernizing hemorrhagic stroke workflows can’t wait
Featuring: Sabareesh Natarajan, MD, MS
Thursday, May 14, 2 PM PT

Register
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
Press Release

iSchemaView's Rapid Approved for Use in Canada

Patients Suffering Ischemic Stroke in Canada Now Have Access to the Only Clinically Validated, Next-Generation Imaging Platform for Assessing Treatment

Share to

Patients Suffering Ischemic Stroke in Canada Now Have Access to the Only Clinically Validated, Next-Generation Imaging Platform for Assessing Treatment

Redwood City, Calif. – August 16, 2018 – iSchemaView, the leader in cerebrovascular imaging analysis, today announced it has received final approval for the use of the RAPID platform in Canada. The RAPID platform is designed to provide physicians with fast, fully automated, elegant and easy-to-interpret imaging that facilitates clinical decision-making around cerebrovascular disease, such as stroke. Canadian approval comes after iSchemaView’s quality system was certified through the Medical Device Single Audit Program (MDSAP) — a global approach to auditing and monitoring the manufacturing of medical devices, in an effort to improve safety and oversight on an international scale. iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the American Heart Association’s and Canadian Heart and Stroke Foundation’s stroke guidelines to include CT perfusion and MR perfusion. The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well. “Our research use of RAPID has shown that its speed and accuracy are very helpful in the management of patients with acute stroke,” said Dr. Frank Silver, Medical Director, Toronto West Stroke Network; Medical Director of the Ontario Telestroke Program and Professor of Neurology at the University of Toronto. “RAPID plays an important role in selecting which patients should be urgently transferred to regional stroke centers for endovascular therapy.” RAPID technology assists physicians in the analysis of brain images using automated tools for CT ASPECTS, CT angiography, CT perfusion and MR diffusion and perfusion for more than 85,000 stroke cases per year. RAPID is also currently deployed in six multi-center clinical trials globally — adding 200 hospitals to RAPID’s global reach. The RAPID neuroimaging platform creates high-quality images from non-contrast CT, CT angiography, CT perfusion and MRI diffusion and perfusion studies. The software provides an intuitive and easily interpretable real-time view of brain perfusion, allowing physicians to determine lesion volumes for a wide variety of different thresholds. Also approved for use in Canada is RAPID ASPECTS, a validated solution that assists clinicians in assessing early signs of brain ischemia in stroke. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. “With approval for RAPID in Canada, we will be able to greatly expand the number of health care facilities that are able to assess stroke patients with the only clinically validated next-generation imaging technology,” said Don Listwin, CEO of iSchemaView. “Over 575 stroke centers in 22 countries around the world have now committed to using the RAPID platform, and we look to increasing that number substantially by the end of the year.” For more information about working with RAPID in Canada, contact Cynthia Yang at +1 (949) 836-7402 or at yang@irapid.com .

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com

Get to know Rapid in the real world

View All Resources
Video - Lumina Webinar Replay

Webinar

The end of manual head & neck reconstructions // A faster path with Lumina 3D

In this webinar, we focus on the challenges and opportunities in 3D head and neck CTA reconstruction workflows. Our speakers share real-world insights on how the Lumina 3D platform can have a tangible impact on CT workflow, scanner throughput, and diagnosis.
Radiology Rewired Podcast - Episode 1 Thumbnail

Podcast

AI Meets Imaging | Radiology Rewired | Ep. 1

In the debut episode of Radiology Rewired, RapidAI’s new clinician-led podcast hosted by Dr. Singh, Dr. Greg Albers—founder of RapidAI and professor of neurology at Stanford University—shares the story behind one of medicine’s most important breakthroughs: extending the stroke treatment window to 24 hours. Dr. Albers recounts how decades of imaging research led from early diffusion-perfusion MRI to automated AI tools that changed global stroke guidelines and transformed how teams diagnose and treat patients. This episode explores how deep clinical AI is reshaping radiology and why credible, clinician-led innovation remains essential for the next generation of healthcare technology.
Resources - multistakeholder white paper

White paper

The clinical AI champion's guide: getting to "yes" in complex health systems

This guide is designed for internal champions, clinicians, service line leaders, and administrators who believe in the potential of AI to improve care and operations. It offers practical insights from a C-suite advisory panel from leading health systems across the nation on how decisions are made, who typically drives them forward, and what tools and strategies are proving most effective in securing alignment and buy-in across the system.